Aquestive Therapeutics to Present Data at the 2026 ACAAI Annual Meeting

Aquestive Therapeutics (NASDAQ: AQST) will present research at the ACAAI Annual Meeting, taking place November 12–16, 2026, in Phoenix, Arizona.

Rhea-AI Summary

Aquestive Therapeutics (NASDAQ: AQST) will present research at the ACAAI Annual Meeting, taking place November 12–16, 2026, in Phoenix, Arizona. Two oral presentations and two posters will cover investigational Anaphylm (dibutepinephrine) sublingual film research and healthcare provider perspectives on epinephrine delivery for anaphylaxis. Topics include drug exposure and effects in the body, allergic-reaction symptoms and top-of-tongue placement.

Key Terms

pharmacokinetic, pharmacodynamic, sublingual film, anaphylaxis

4 terms

pharmacokinetic medical

"pharmacokinetic and pharmacodynamic profile of its investigational product candidate"

Pharmacokinetic describes how a drug moves through and leaves the body — how it is absorbed, spread to tissues, broken down and excreted — like tracking a package from pickup to delivery and disposal. For investors, these properties determine effective dose, safety risks, how often a medicine must be taken, and how reliably it works, which in turn influence clinical trial success, regulatory approval chances, production complexity and a drug’s commercial value.

pharmacodynamic medical

"pharmacokinetic and pharmacodynamic profile of its investigational product candidate"

Pharmacodynamic describes how a drug acts on the body — the biological effects it produces, how strong those effects are, and how long they last. For investors, pharmacodynamic data show whether a treatment actually works and at what dose, shaping expectations about a drug’s safety, effectiveness, regulatory success and market potential; think of it like testing how well a key turns a lock and whether it reliably opens the door.

sublingual film medical

"Anaphylm™ (dibutepinephrine) sublingual film"

A sublingual film is a thin, dissolvable strip placed under the tongue that releases medication so it can be absorbed directly into the bloodstream through the mouth’s tissue. For investors, the delivery method matters because it can speed onset, avoid swallowing or injections, simplify dosing and manufacturing, and affect patient preference and regulatory approval — all factors that influence a product’s market potential and cost structure.

anaphylaxis medical

"epinephrine delivery for the treatment of anaphylaxis"

Anaphylaxis is a sudden, severe allergic reaction in which the body's defense system overreacts to a trigger (like a drug, food, or insect sting), causing widespread symptoms such as difficulty breathing, low blood pressure, and shock; it can be life‑threatening without prompt treatment. Investors care because anaphylaxis risks can affect a drug or product's safety profile, regulatory approval, liability exposure and market acceptance—similar to a sprinkler system going off and damaging the whole house rather than just one room.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

WARREN, N.J., Nov. 05, 2026 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (“Aquestive” or the “Company”), a biopharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science, today announced that multiple oral and poster presentations will be featured at the 2026 American College of Allergy, Asthma, and Immunology (ACAAI) Annual Meeting, taking place November 12-16, 2026, in Phoenix, Arizona. The presentations will highlight research evaluating the pharmacokinetic and pharmacodynamic profile of its investigational product candidate Anaphylm™ (dibutepinephrine) sublingual film and healthcare provider perspectives on epinephrine delivery for the treatment of anaphylaxis.

An oral presentation, titled “Dibutepinephrine Pharmacokinetics/Pharmacodynamics in Patients With and Without Symptoms of a Type I Allergic Reaction,” is scheduled to be presented during Distinguished Industry and Late-breaking Oral Abstracts – Session 1 on Saturday, November 14, 2026, at 4:43 pm MST, by Jay A. Lieberman, MD.

An oral presentation, titled “Pharmacokinetics and Pharmacodynamics of Top-of-Tongue Placement of Dibutepinephrine Sublingual Film” is scheduled to be presented during Distinguished Industry and Late-breaking Oral Abstracts – Session 1 on Saturday, November 14, 2026, at 5:23 pm MST, by Matthew Greenhawt, MD, MBA, MSc.

Poster presentation details are as follows:

Poster Title: Healthcare Provider Perspectives on Unmet Needs and Clinical Considerations for Epinephrine Delivery in Anaphylaxis
Lead Author: Karen Rance, DNP, CPNP
Presentation Time: Friday, Nov. 13 at 3:05 pm MST

Poster Title: Pharmacodynamic Effects of Sublingual Epinephrine Film AQST-109 at Low Systemic Epinephrine Exposures
Lead Author: David B.K. Golden, MD
Presentation Time: Friday, Nov. 13, at 3:20 pm MST

The abstracts will be available online at annualmeeting.acaai.org on November 12, 2026.

About Anaphylm™ (dibutepinephrine) Sublingual Film

Anaphylm™ (dibutepinephrine) Sublingual Film is a polymer matrix-based epinephrine prodrug product candidate. Anaphylm is similar in size to a postage stamp, weighs less than an ounce, and begins to dissolve on contact. No water or swallowing is required for administration. The packaging for Anaphylm is thinner and smaller than an average credit card, can be carried in a phone or wallet, and is designed to withstand weather excursions such as exposure to rain and/or sunlight. If approved by the United States Food and Drug Administration (FDA), Anaphylm would be the first and only oral rescue medication for the treatment of severe allergic reactions, including anaphylaxis. The Anaphylm trade name for AQST-109 has been conditionally approved by the FDA. Final approval of the Anaphylm proprietary name is conditioned on FDA approval of the product candidate.

About Aquestive Therapeutics

Aquestive is a biopharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science. The worldwide leader in delivering trusted, quality medications on oral film, Aquestive operates with its headquarters in New Jersey and U.S.-based manufacturing facilities in Indiana. The Company is the exclusive manufacturer of four commercialized products marketed by its licensees across six continents using proprietary, best-in-class technologies like PharmFilm^®. Aquestive's AdrenaVerse™ platform contains a library of more than 20 epinephrine prodrugs enabling the pursuit of various potential allergy and dermatological indications. The Company is advancing Anaphylm™ (dibutepinephrine) sublingual film for the treatment of Type I allergic reactions, including anaphylaxis, and AQST-108 (epinephrine) topical gel for various potential dermatological conditions. For more information, visit Aquestive.com and follow us on LinkedIn.

Forward-Looking Statement

Certain statements in this press release include "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "believe," "anticipate," "plan," "expect," "estimate," "intend," "may," "will," or the negative of those terms, and similar expressions, are intended to identify forward-looking statements. These forward-looking statements include, but are not limited to, statements regarding the advancement and related timing of Anaphylm™ (dibutepinephrine) sublingual film for the proposed indication of severe allergic reactions, including anaphylaxis through the U.S. Food and Drug Administration regulatory review and approval process; the potential benefits Anaphylm could bring to patients, and other statements that are not historical facts.

These forward-looking statements are based on our current expectations and beliefs and are subject to a number of risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Such risks and uncertainties include, but are not limited to, risks associated with the Company’s development work, including delays to the timing, costs and success of its product development activities, clinical trials and regulatory applications, including relating to Anaphylm (dibutepinephrine) sublingual film, and other uncertainties affecting the Company described in the "Risk Factors" section and elsewhere in the Company's Annual Report on Form 10-K, Quarterly Reports on Form 10-Q and Current Reports on Form 8-K filed with the U.S. Securities and Exchange Commission. Given those uncertainties, you should not place undue reliance on these forward-looking statements, which speak only as of the date made. All subsequent forward-looking statements attributable to the Company or any person acting on its behalf are expressly qualified in their entirety by this cautionary statement. The Company undertakes no obligation to update any forward-looking statement after the date of this press release, whether as a result of new information, future events or otherwise, except as required by applicable law.

PharmFilm® and the Aquestive logo are registered trademarks of Aquestive Therapeutics, Inc.

Investor Contact:
Brian Korb
astr partners
brian.korb@astrpartners.com